Table 2 Patients who stopped tolvaptan treatment due to improved ascites
From: Impact of continued administration of tolvaptan on cirrhotic patients with ascites
Age (years old) | Sex | Etiology of liver disease | Tolvaptan treatment (days) | Requirement for restarting of tolvaptan | Furosemide (mg/day) | Spironolactone (mg/day) | Modified CP score | Event |
|---|---|---|---|---|---|---|---|---|
60s | Male | Alcoholic liver disease | 126 | 80 | 400 | 11 | Discontinued drinking | |
40s | Male | Hepatitis C virus-related liver disease+ alcoholic liver disease | 1226 | Yes | 20 | 25 | 13 | Discontinued drinking |
40s | Male | Alcoholic liver disease | 49 | Yes | 20 | 100 | 12 | Discontinued drinking |
70s | Male | Primary sclerosing cholangitis | 335 | 160 | 100 | 11 | Decreased protein urea | |
60s | Male | Hepatitis B virus-related liver disease | 249 | Yes | 20 | 25 | 10 | Treatment with nucleic acid analog |
80s | Female | Hepatitis C virus-related liver disease | 187 | 20 | 50 | 8 | Disappearance of portal vein thrombosis | |
70s | Male | Alcoholic liver disease | 293 | 20 | 25 | 10 | Discontinued drinking | |
60s | Male | Alcoholic liver disease+MTX associated liver disease | 186 | 10 | 25 | 11 | Discontinued MTX | |
60s | Female | Alcoholic liver disease | 139 | 10 | 25 | 12 | Discontinued drinking |